Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 3

Тяжелая бронхиальная астма-2018. Согласительный доклад объединенной группы экспертов Ассоциации русскоговорящих специалистов в области респираторной медицины, Российского респираторного общества, Российской ассоциации аллергологов и клинических иммунолого
Т.В. Барановская, А.С. Белевский, А.Г. Восканян, К.М. Гаджиев, Н.Э. Давлеталиева, А.В. Емельянов, О.М. Курбачева, Н.П. Княжеская, И.Ю. Мукатова, Н.М. Ненашева от имени объединенной группы экспертов

References
1. Global Strategy for Asthma Management and Prevention. Revised 2018. Available from: www.ginasthma.com Accessed 2018 Nov 15.
2. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. The European Respiratory Journal 2014 Feb;43(2):343-73.
3. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Respiratory Medicine 2017 Sep;5(9):691-706.
4. Chuchalin AG, Khaltaev N, Аntonov N, Galkin DV, Manakov LG, Antonini P, Murphy M, Solodovnikov AG, Bousquet J, Pereira MH, Demko IV. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease 2014 Sep;9:963-74.
5. Chuchalin AG, Abelevich MM, Arkhipov VV, Astafyeva NG, Asherova KI, Balabolkin II, Baleva LS, Baskakova AE, Blokhin BM, Bogorad AE, Brisin VYu, Volkov IK, Geppe NA, Golovin MB, Goryachkina LA, Dronov IA, Elkina TN, Ermakova IN, Ermakova M K, Zhakov YaI, Zabolotskikh TV, Zaytseva OV, Ivanova NA, Ilyenkova NA, Ilyina NI, Kamaev AV, Kovanova MN, Kozhevnikova TN, Kozlov VK, Kozlov LV, Kolosova NG, Kondyurina EG, Korostovtsev DS, Kulagina VV, Kulikova NI, Lee TS, Lipina VP, Lukina OF, Makarova IV, Malakhov AB, Malanicheva TG, Mashukova NG, Melnikova IM, Meshcheryakov VV, Mizernitskiy YuL, Mokina NA, Nenasheva NM, Neretina AF, Ogorodova LM, Pochivalov AV, Prodeus AP, Revyakina VA, Rozinova NN, Ryvkin AI, Savvina NV, Sentsova TB, Sidorenko IV, Skachkova MA, Soroka ND, Spichak TV, Fayzullina RM, Furman EG, Tsarkova SA, Chepurnaya MM, Sharovskaya GI, Shcherbina AYu, Sheplyagina LA, Erdes SI. Bronchial asthma in children: treatment strategy and prevention. National program. 4th ed., revised. Moscow, 2012. 184 p. (In Russian).
6. Sergeyeva GR, Emelyanov AV, Korovina OV, Znakhurenko AA, Leshenkova EV, Kozyreva LV, Asatiani N. Severe asthma: characteristics of patients in clinical practice. Therapeutic Archive 2015;87(12):26-31 (In Russian).
7. Bousqet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, Casale TB, Chan-Yeung M, Chen R, Chowdhury B, Chung KF, Dahl R, Drazen JM, Fabbri LM, Holgate ST, Kauffmann F, Haahtela T, Khaltaev N, Kiley JP, Masjedi MR, Mohammad Y, O’Byrne P, Partridge MR, Rabe KF, Togias A, van Weel C, Wenzel S, Zhong N, Zuberbier T. Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. Journal of Allergy and Clinical Immunology 2010 Nov;126(5):926-38.
8. Russian Respiratory Society. Diagnosis and treatment of bronchial asthma: Federal clinical guidelines 2017. Available at: www.pulmonology.ru Accessed 2018 Nov 15. (In Russian).
9. Nenasheva NM. Biological therapy of asthma: present and future. Consilium Medicum 2016;18(11):30-8 (In Russian).
10. Peters SP, Jones SP, Haselkorn SP, Mink DR, Valacer DJ, Weiss ST. Real-World Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. Journal of Allergy and Clinical Immunology 2007 Jun;119(6):1454-61.
11. Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA Jr, Gern J, Heymann PW, Martinez FD, Mauger D, Teague WG, Blaisdell C. Asthma outcomes: exacerbations. The Journal of Allergy and Clinical Immunology 2012 Mar;129(3 Suppl):S34-48.
12. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. Journal of Allergy and Clinical Immunology 2015 Apr;135(4):896-902.
13. Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new-targeted therapies. Journal of Internal Medicine 2016;279:192-204.
14. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, Chung KF, Curran-Everett D, Dweik RA, Fain SB, Fitzpatrick AM, Gaston BM, Israel E, Hastie A, Hoffman EA, Holguin F, Levy BD, Meyers DA, Moore WC, Peters SP, Sorkness RL, Teague WG, Wenzel SE, Busse WW; NHLBI Severe asthma Research Program (SARP). Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. American Journal of Respiratory and Critical Care Medicine 2012 Feb;185(4):356-62.
15. Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics 2013;7:7-11.
16. Instructions for medical use of Cinqeiro (Reslizumab). Registration no LP-004265. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d2f201db-73ab-465c-afb8-3a04f78e1608&t= Accessed 2018 Nov 15 (In Russian).
17. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double blind, randomised, placebo-controlled, phase 3 trials. The Lancet Respiratory Medicine 2015 May;3(5):355-66.
18. Murphy K, Jacobs J, Bjermer L, Shalit Y, Garin M. Long-term safety and efficacy ofreslizumab in patients with inadequately controlled, moderate-to-severe asthma and elevated blood eosinophil counts: an open-label extension study. Presented at the American Thoracic Society (ATS) International Conference; 2015 May 15-20; Denver, Colorado.
19. Data on file (Clinical study report: a 12-month, double blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Reslizumab [3.0 mg/kg] in the reduction of clinical asthma exacerbations in patients [12-75 years of age] with eosinophilic asthma. Study C38072/3082). Summary 15.47. Horsham, PA: Teva Respiratory, LLC; 2015.
20. Cinqair prescribing information. Horsham, PA: Teva Respiratory, LLC; 2016.
21. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 2011 Nov;184(10):1125-32.
22. Instructions for medical use of Nukala. Registration no. LP-004794. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c9500b78-9cf6-45c9-8336-16ef5348b722&t= Accessed 2018 Nov 15 (In Russian).
23. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. The Lancet Respiratory Medicine 2016 Jul;4(7):549-56.
24. Chupp GL Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. The Lancet Respiratory Medicine 2017 May;5(5):390-400.
25. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. The New England Journal of Medicine 2014 Sep;371(13):1189-97.
26. Kurbacheva OM, Pavlova KS. Phenotypes and endotypes of bronchial asthma: from pathogenesis and clinical features to therapy. Russian Allergology Journal 2013;1:15-24 (In Russian).
27. Stephenson L. Monoclonal antibody therapy for asthma. Clinical Pulmonary Medicine 2017 Nov;24(6):250-7.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]